# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
Piper Sandler analyst David Westenberg maintains Elanco Animal Health (NYSE:ELAN) with a Neutral and lowers the price target...
Barclays analyst Balaji Prasad maintains Elanco Animal Health (NYSE:ELAN) with a Overweight and lowers the price target from...
Elanco Animal Health shares drop after updates on FDA approval timelines for Zenrelia and Credelio Quattro. Zenrelia's U.S....